Literature DB >> 34134474

Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.

Sonali Smith1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34134474      PMCID: PMC8804557          DOI: 10.3324/haematol.2021.279101

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.

Authors:  Chadi Nabhan; Nicholas J Ollberding; Dana Villines; Brian C-H Chiu; Donne Bennett D Caces; Tina V Valdez; Michele Ghielmini; Shu-Fang Hsu Schmitz; Sonali M Smith
Journal:  Leuk Lymphoma       Date:  2013-11-01

2.  Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Authors:  Wolfgang Hiddemann; Anna Maria Barbui; Miguel A Canales; Paul K Cannell; Graham P Collins; Jan Dürig; Roswitha Forstpointner; Michael Herold; Mark Hertzberg; Magdalena Klanova; John Radford; John F Seymour; Kensei Tobinai; Judith Trotman; Alis Burciu; Günter Fingerle-Rowson; Marcel Wolbers; Tina Nielsen; Robert E Marcus
Journal:  J Clin Oncol       Date:  2018-06-01       Impact factor: 44.544

3.  Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.

Authors:  Lucio N Gordan; William B Grow; Annette Pusateri; Vonda Douglas; Nancy P Mendenhall; James W Lynch
Journal:  J Clin Oncol       Date:  2005-01-18       Impact factor: 44.544

4.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

Review 5.  Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

Authors:  Liat Vidal; Anat Gafter-Gvili; Gilles Salles; Martin H Dreyling; Michele Ghielmini; Shu-Fang Hsu Schmitz; Ruth Pettengell; Mathias Witzens-Harig; Ofer Shpilberg
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506

6.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

Authors:  N L Berinstein; A J Grillo-López; C A White; I Bence-Bruckler; D Maloney; M Czuczman; D Green; J Rosenberg; P McLaughlin; D Shen
Journal:  Ann Oncol       Date:  1998-09       Impact factor: 32.976

7.  Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Authors:  Brad S Kahl; Fangxin Hong; Michael E Williams; Randy D Gascoyne; Lynne I Wagner; John C Krauss; Thomas M Habermann; Lode J Swinnen; Stephen J Schuster; Christopher G Peterson; Mark D Sborov; S Eric Martin; Matthias Weiss; W Christopher Ehmann; Sandra J Horning
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

8.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Irit Avivi; Anat Aharon; Gabi Shefer; Shai Levi; Yotam Bronstein; Miguel Morales; Tomer Ziv; Yamit Shorer Arbel; Lydia Scarfò; Erel Joffe; Chava Perry; Paolo Ghia
Journal:  Blood       Date:  2021-06-10       Impact factor: 22.113

9.  Outcomes of COVID-19 in patients with CLL: a multicenter international experience.

Authors:  Anthony R Mato; Lindsey E Roeker; Nicole Lamanna; John N Allan; Lori Leslie; John M Pagel; Krish Patel; Anders Osterborg; Daniel Wojenski; Manali Kamdar; Scott F Huntington; Matthew S Davids; Jennifer R Brown; Darko Antic; Ryan Jacobs; Inhye E Ahn; Jeffrey Pu; Krista M Isaac; Paul M Barr; Chaitra S Ujjani; Mark B Geyer; Ellin Berman; Andrew D Zelenetz; Nikita Malakhov; Richard R Furman; Michael Koropsak; Neil Bailey; Lotta Hanson; Guilherme F Perini; Shuo Ma; Christine E Ryan; Adrian Wiestner; Craig A Portell; Mazyar Shadman; Elise A Chong; Danielle M Brander; Suchitra Sundaram; Amanda N Seddon; Erlene Seymour; Meera Patel; Nicolas Martinez-Calle; Talha Munir; Renata Walewska; Angus Broom; Harriet Walter; Dima El-Sharkawi; Helen Parry; Matthew R Wilson; Piers E M Patten; José-Ángel Hernández-Rivas; Fatima Miras; Noemi Fernández Escalada; Paola Ghione; Chadi Nabhan; Sonia Lebowitz; Erica Bhavsar; Javier López-Jiménez; Daniel Naya; Jose Antonio Garcia-Marco; Sigrid S Skånland; Raul Cordoba; Toby A Eyre
Journal:  Blood       Date:  2020-09-03       Impact factor: 25.476

10.  Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.

Authors:  Simon Rule; Wolney Gois Barreto; Javier Briones; Angelo M Carella; Olivier Casasnovas; Chris Pocock; Clemens-Martin Wendtner; Francesco Zaja; Susan Robson; Lachlan MacGregor; Roger R Tschopp; Sonja Nick; Martin Dreyling
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.